CrystagenvsEpithalon

Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.

Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.

As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary reported mechanism is the activation of telomerase — the ribonucleoprotein enzyme complex responsible for maintaining telomere length at chromosome ends.

Telomeres are repetitive nucleotide sequences (TTAGGG in humans) that cap and protect chromosome ends from degradation, fusion, and recognition as DNA damage. With each cell division, the DNA replication machinery cannot fully copy the very end of the lagging strand (the 'end replication problem'), resulting in progressive telomere shortening. When telomeres reach a critical length, cells enter replicative senescence (permanent growth arrest) or apoptosis — a fundamental mechanism of cellular aging. Telomerase, composed of the catalytic subunit hTERT (human telomerase reverse transcriptase) and the RNA template component hTR/TERC, can add TTAGGG repeats back to chromosome ends, counteracting this shortening.

Epithalon reportedly activates the expression of the hTERT gene, increasing telomerase activity in somatic cells. In cell culture studies, epithalon treatment was associated with increased telomere length and extended replicative lifespan in human fibroblasts and retinal pigment epithelial cells. The peptide also reportedly stimulates melatonin production by the pineal gland, potentially through gene-regulatory effects on pineal cells. Melatonin itself is a potent antioxidant and circadian regulator, and its decline with age correlates with numerous age-related changes. Additional reported effects include normalization of T-cell function, modulation of neuroendocrine signaling, and improved antioxidant enzyme expression. It should be noted that the majority of published research comes from Russian institutions, and large-scale, peer-reviewed Western clinical trials are lacking.